{"url":"https://nivawealth.com/firms/lynx1-capital-management-310301","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/310301","regulatoryAum":626680245,"crd":"310301","history":[{"filedOn":"2023-03-03","regulatoryAum":136423000,"clients":3,"employees":3,"offices":1},{"filedOn":"2024-03-26","regulatoryAum":268343489,"clients":4,"employees":3,"offices":1},{"filedOn":"2025-06-23","regulatoryAum":310306368,"clients":5,"employees":5,"offices":1},{"filedOn":"2026-03-31","regulatoryAum":626680245,"clients":5,"employees":5,"offices":1}],"secFileNumber":"801-127585","legalName":"Lynx1 Capital Management LP","displayName":"Lynx1 Capital Management","slug":"lynx1-capital-management-310301","website":null,"classification":{"segment":"private_funds","segmentLabel":"Private funds","type":"private_fund_manager","typeLabel":null,"feeDisclosure":"payment_only"},"founded":null,"organization":"Delaware limited partnership","fiscalYearEnd":"December","headquarters":{"street":"D81 Calle C, Suite 301 PMB 1202","city":"Dorado","state":"PR","stateName":"Puerto Rico","country":"United States","postalCode":"00646"},"tradeNames":[],"registration":{"secApproved":"5 April 2023","noticeFilings":null,"latestNoticeFiling":null},"wealthAumPerClient":null,"staff":{"employees":5,"advisory":4,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"regulatory":626680245,"discretionary":626680245,"discretionaryAccounts":5,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":40,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":5,"regulatoryAum":626680245}],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Lynx1 Capital Management has custody of $577M for 4 clients.","otherCustodians":[],"leadership":[{"name":"Nathali Partyka Zamora","title":"Chief Compliance Officer","crd":"7643118"},{"name":"Weston Nichols","title":"Chief Investment Officer, Limited Partner","crd":"6325567"}],"ownership":[{"label":"Weston Nichols","detail":"Chief investment officer, limited partner in the 75% or more ownership band and a control person, since May 2020. Also a sole member of Lynx1 Capital Management GP LLC in the 75% or more band and a control person, since May 2020."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":0,"privateResidences":0},"listedOfficeAddresses":1,"foreignOffices":[],"officesByState":[{"state":"Puerto Rico","offices":1,"addresses":[{"street":"D81 Calle C, Suite 301 PMB 1202","city":"Dorado","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"929-888-7476","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":"0","assetMix":[],"privateFunds":2},"sources":{"adv1FilingDate":"31 March 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/310301/PDF/310301.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","updatedOn":"2026-10-21","holdingsUpdatedOn":"2026-10-21","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Lynx1 Capital Management have?","answer":"Lynx1 Capital Management has 5 clients and manages $627 million for them, as of March 2026. They include 5 pooled investment vehicles.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Lynx1 Capital Management offer?","answer":"Lynx1 Capital Management provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Lynx1 Capital Management have?","answer":"Lynx1 Capital Management has 0 investment adviser representatives registered with state securities authorities, out of 5 employees, and 4 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Lynx1 Capital Management?","answer":"Lynx1 Capital Management’s direct owner is Weston Nichols (75% or more).","source":"Form ADV Part 1A, Schedules A and B, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Lynx1 Capital Management get paid?","answer":"Lynx1 Capital Management is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How do I contact Lynx1 Capital Management?","answer":"Lynx1 Capital Management’s main office is at D81 Calle C, Suite 301 PMB 1202, Dorado, PR 00646. Its phone number is 929-888-7476.","source":"Form ADV Part 1A, Item 1.F, filed 31 March 2026","sourceRef":{"doc":"adv1","section":"offices"}}],"holdings":{"url":"https://nivawealth.com/firms/lynx1-capital-management-310301/holdings","form":"13F-HR","periodOfReport":"2026-06-30","filedOn":"2026-08-13","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1910456/000191045626000004/0001910456-26-000004-index.html","totalValue":865529222,"positionCount":27,"top10Share":0.9882029032175184,"top10":[{"issuer":"GH RESEARCH PLC","titleOfClass":"ORDINARY SHARES","cusip":"G3855L106","value":356517181,"shares":13263288,"shareType":"SH","priorValue":151331829,"priorShares":10763288},{"issuer":"CULLINAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"230031106","value":163225335,"shares":8963500,"shareType":"SH","priorValue":127371335,"priorShares":8963500},{"issuer":"STOKE THERAPEUTICS INC","titleOfClass":"COM","cusip":"86150R107","value":132136579,"shares":4038404,"shareType":"SH","priorValue":155105193,"priorShares":4763673},{"issuer":"AGIOS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"00847X104","value":126505652,"shares":3408937,"shareType":"SH","priorValue":88349345,"priorShares":2611568},{"issuer":"C4 THERAPEUTICS INC","titleOfClass":"COM STK","cusip":"12529R107","value":34215647,"shares":7326691,"shareType":"SH","priorValue":18407112,"priorShares":6998902},{"issuer":"KORRO BIO INC","titleOfClass":"COM","cusip":"500946108","value":20274741,"shares":1538296,"shareType":"SH","priorValue":17413511,"priorShares":1538296},{"issuer":"TSCAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"89854M101","value":7859567,"shares":8019148,"shareType":"SH","priorValue":8099339,"priorShares":8019148},{"issuer":"PRECISION BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"74019P207","value":7470663,"shares":950466,"shareType":"SH","priorValue":5418122,"priorShares":985113},{"issuer":"NEUPHORIA THERAPEUTICS INC","titleOfClass":"COM","cusip":"64136E102","value":3825183,"shares":875328,"shareType":"SH","priorValue":3562585,"priorShares":875328},{"issuer":"PASSAGE BIO INC","titleOfClass":"COM NEW","cusip":"702712209","value":3287942,"shares":673759,"shareType":"SH","priorValue":4896076,"priorShares":623704}],"positionsListed":27,"positions":[{"issuer":"GH RESEARCH PLC","titleOfClass":"ORDINARY SHARES","cusip":"G3855L106","value":356517181,"shares":13263288,"shareType":"SH","priorValue":151331829,"priorShares":10763288},{"issuer":"CULLINAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"230031106","value":163225335,"shares":8963500,"shareType":"SH","priorValue":127371335,"priorShares":8963500},{"issuer":"STOKE THERAPEUTICS INC","titleOfClass":"COM","cusip":"86150R107","value":132136579,"shares":4038404,"shareType":"SH","priorValue":155105193,"priorShares":4763673},{"issuer":"AGIOS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"00847X104","value":126505652,"shares":3408937,"shareType":"SH","priorValue":88349345,"priorShares":2611568},{"issuer":"C4 THERAPEUTICS INC","titleOfClass":"COM STK","cusip":"12529R107","value":34215647,"shares":7326691,"shareType":"SH","priorValue":18407112,"priorShares":6998902},{"issuer":"KORRO BIO INC","titleOfClass":"COM","cusip":"500946108","value":20274741,"shares":1538296,"shareType":"SH","priorValue":17413511,"priorShares":1538296},{"issuer":"TSCAN THERAPEUTICS INC","titleOfClass":"COM","cusip":"89854M101","value":7859567,"shares":8019148,"shareType":"SH","priorValue":8099339,"priorShares":8019148},{"issuer":"PRECISION BIOSCIENCES INC","titleOfClass":"COM NEW","cusip":"74019P207","value":7470663,"shares":950466,"shareType":"SH","priorValue":5418122,"priorShares":985113},{"issuer":"NEUPHORIA THERAPEUTICS INC","titleOfClass":"COM","cusip":"64136E102","value":3825183,"shares":875328,"shareType":"SH","priorValue":3562585,"priorShares":875328},{"issuer":"PASSAGE BIO INC","titleOfClass":"COM NEW","cusip":"702712209","value":3287942,"shares":673759,"shareType":"SH","priorValue":4896076,"priorShares":623704},{"issuer":"CG ONCOLOGY INC","titleOfClass":"COM","cusip":"156944100","value":2230331,"shares":31391,"shareType":"SH","priorValue":2138079,"priorShares":31591},{"issuer":"PLIANT THERAPEUTICS INC","titleOfClass":"COM","cusip":"729139105","value":2049800,"shares":1798070,"shareType":"SH"},{"issuer":"ENTRADA THERAPEUTICS INC","titleOfClass":"COM","cusip":"29384C108","value":1314540,"shares":178606,"shareType":"SH","priorValue":2671515,"priorShares":211689},{"issuer":"VYNE THERAPEUTICS INC","titleOfClass":"COM","cusip":"92941V308","value":1059795,"shares":1628700,"shareType":"SH","priorValue":973148,"priorShares":1628700},{"issuer":"PROQR THRAPEUTICS N V","titleOfClass":"SHS EURO","cusip":"N71542109","value":969828,"shares":521413,"shareType":"SH","priorValue":110947,"priorShares":68486},{"issuer":"TRAWS PHARMA INC","titleOfClass":"COM NEW","cusip":"68232V884","value":471801,"shares":559470,"shareType":"SH","priorValue":27593,"priorShares":15078},{"issuer":"FOGHORN THERAPEUTICS INC","titleOfClass":"COM","cusip":"344174107","value":300549,"shares":61588,"shareType":"SH"},{"issuer":"DENALI THERAPEUTICS INC","titleOfClass":"COM","cusip":"24823R105","value":299844,"shares":11658,"shareType":"SH","priorValue":36101818,"priorShares":1880303},{"issuer":"XENCOR INC","titleOfClass":"COM","cusip":"98401F105","value":292923,"shares":18194,"shareType":"SH","priorValue":6468960,"priorShares":536398},{"issuer":"ABSCI CORPORATION","titleOfClass":"COM","cusip":"00091E109","value":246230,"shares":21245,"shareType":"SH","priorValue":63735,"priorShares":21245},{"issuer":"WEREWOLF THERAPEUTICS INC","titleOfClass":"COM","cusip":"95075A107","value":236737,"shares":657786,"shareType":"SH","priorValue":547673,"priorShares":657786},{"issuer":"IMMATICS N.V","titleOfClass":"SHS","cusip":"N44445109","value":235381,"shares":23236,"shareType":"SH","priorValue":2135014,"priorShares":216973},{"issuer":"AVALO THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"05338F306","value":186648,"shares":10100,"shareType":"SH"},{"issuer":"BOLT BIOTHERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"097702203","value":118580,"shares":30800,"shareType":"SH","priorValue":124432,"priorShares":30800},{"issuer":"NUVATION BIO INC","titleOfClass":"COM CL A","cusip":"67080N101","value":91045,"shares":16029,"shareType":"SH"},{"issuer":"EUPRAXIA PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"29842P105","value":66100,"shares":10000,"shareType":"SH"},{"issuer":"INHIBIKASE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"45719W205","value":40600,"shares":20000,"shareType":"SH"}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}